Clinical trials often involve a research study conducted to evaluate a medical procedure or medical product, such as a drug. Not all University of Arizona studies involve drugs or interventions. Some studies use surveys or evaluate medical records to find new and better ways to help people. Others recruit healthy subjects, or controls, to better evaluate and compare results with those of non-healthy subjects.
How to Participate
Whether you’re a potential candidate to participate as a patient or subject in the study, you would like to participate as a "healthy volunteer" for the control group or you’re a research or clinical professional interested in collaborating with the research team—simply contact the study coordinator listed for each individual clinical research study below.
For medical emergencies, please dial 9-1-1.
To contact the Division of Nephrology directly, call (520) 626-6371.
To contact the study coordinators, call the numbers listed below:
- Ellen Santos, MS: (520) 626-3531
- Studies: PRO2TECT CONVERSION & CORRECTION, LOCK-IT-100, The Access Trial (VT-304)
- Ana Florea, MPH: (520) 626-2912
- Studies: FIDELIO-DKD 16244 & FIGARO-DKD 17530, 1407-004, RMCL-002
- Tom Jan, BS: (520) 626-3283
- Studies: PRT-201-320, ALXN1210-aHUS-311
Current Clinical Trials
The following trials are active and currently enrolling new volunteers:
FIDELIO-DKD (16244): A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. https://clinicaltrials.gov/ct2/show/NCT02540993
FIGARO-DKD (17530): A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. https://clinicaltrials.gov/ct2/show/NCT02545049
PRO2TECT-CORRECTION (AKB-6548-CI-0014): Phase III, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD). https://clinicaltrials.gov/ct2/show/NCT02648347
PRO2TECT-CONVERSION (AKB-6548-CI-0015): Phase III, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD). https://clinicaltrials.gov/ct2/show/NCT02680574
PRT-201-320: Multicenter, double-blind, placebo-controlled study of vonapanitase (PRT-201) administered immediately after radiocephalic arteriovenous fistula creation in patients with chronic kidney disease. https://clinicaltrials.gov/ct2/show/NCT02414841
LOCK-IT-100: A phase 3, prospective, multicenter, double-blind, randomized, active control study to demonstrate the safety and effectiveness of Neutrolin in preventing catheter-related bloodstream infections in subjects receiving hemodialysis therapy as treatment for end stage renal disease. https://clinicaltrials.gov/ct2/show/NCT02651428
The Access Trial (VT-304): A phase 3, randomized, multicenter, single-blind controlled study evaluating arteriovenous fistula outcomes with and without a perivascular sirolimus-eluting collagen implant in subjects on hemodialysis. https://clinicaltrials.gov/ct2/show/NCT02513303
RMCL-002: A phase 2, randomized, open-label trial seeking to compare the safety and efficacy of the Neo-Kidney Augment (NKA) in patierts with Type-2 diabetes and CKD. https://clinicaltrials.gov/ct2/show/NCT02836574
ALXN1210-aHUS-311: A phase 3, open label, single-arm study seeking to control the disease effects caused by Atypical Hemolytic Uremic Syndrome (aHUS). https://clinicaltrials.gov/ct2/show/NCT02949128
1407-004: Clinical evaluation of use of prismocitrate 18 in patients undergoing acute continuous renal replacement therapy (CRRT). https://clinicaltrials.gov/ct2/show/NCT02860130